Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Meredith McKean, MD, MPH
Sarah Cannon and HCA Research Institute
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cliniques Universitaires Saint-Luc
Brussels, Belgium
- Institut Jules Bordet
Brussels, Belgium
- Antwerp University Hospital (uza)
Edegem, Belgium
- Universitair Ziekenhuis Gent (uz)
Ghent, Belgium
- Gachon University Gil Medical Center
Incheon, South Korea
- Severance Hospital, Yonsei University Health System
Seoul, South Korea
- Hospital Universitario Vall D'Hebron
Barcelona, Spain
- Institut Catala D'Oncologia - L'Hospitalet
Barcelona, Spain
- Centro Integral Oncologico Clara Campal
Madrid, Spain
- Hospital Fundación Jimenez Diaz
Madrid, Spain
- Hospital Universitario 12 de Octubre
Madrid, Spain
- Sarah Cannon Research Institute Uk
London, United Kingdom, United Kingdom
- the Christie Nhs Foundation Trust
Manchester, United Kingdom, United Kingdom
- Cambridge University Hospitals Nhs Foundation Trust
Cambridge, United Kingdom
- the Leeds Teaching Hospitals Nhs Trust of Trust Headquarters, St James'S University Hospital
Leeds, United Kingdom
- Sir Bobby Robson Cancer Trials Research Centre, the Northern Center for Cancer Care, Freeman Hospital
Newcastle upon Tyne, United Kingdom
- California Cancer Associates for Research and Excellence, Inc.
Encinitas, California, United States
- University of California - Irvine Medical Center
Orange, California, United States
- Sarah Cannon Research Institute at Healthone
Denver, Colorado, United States
- Florida Cancer Specialists
Sarasota, Florida, United States
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Stephenson Cancer Center (oklahoma University)
Oklahoma City, Oklahoma, United States
- Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
- Sarah Cannon and Hca Research Institute
Nashville, Tennessee, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Virginia Cancer Specialists
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Nov 2019
- Primary completion
- 31 Jul 2026
- Completion
- 31 Jul 2027
- Last update posted
- 17 Nov 2025
- Registered enrollment
- 288
- Registry id
- NCT04180371
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.